Building value through precision science
Inhibrx Biosciences (NASDAQ: INBX) is a clinical-stage biopharmaceutical company advancing a differentiated pipeline of multivalent and multispecific biologics for oncology and rare diseases.
Investment Thesis
A differentiated platform with multiple shots on goal
Proprietary sdAb Platform
Our single-domain antibody technology enables the creation of multivalent and multispecific biologics that conventional antibody formats cannot achieve — providing a durable competitive moat.
Validated by Sanofi
The sale of INBRX-101 to Sanofi provided both financial validation of our platform and the capital to advance our remaining pipeline programs independently.
Multiple Clinical Programs
With programs in Phase 1 and Phase 2 across oncology and rare disease, we offer investors diversified exposure to multiple potential value-creating catalysts.
Focused Execution
As a lean, science-first organization, we allocate capital efficiently — maximizing the probability of clinical success across our portfolio.
News & Press
Latest updates
Inhibrx Biosciences Reports Updated Phase 2 Data for INBRX-109 in Chondrosarcoma
Updated clinical data from the Phase 2 study of INBRX-109 in conventional chondrosarcoma presented at a major oncology conference.
Inhibrx Biosciences Announces First Quarter 2024 Financial Results
Company reports financial results for Q1 2024 and provides corporate update on pipeline progress and strategic priorities.
INBRX-106 Phase 1 Dose Escalation Continues with Encouraging Safety Profile
Ongoing Phase 1 study of INBRX-106, a hexavalent OX40 agonist, continues dose escalation with favorable tolerability data.
SEC Filings
Financial disclosures
Inhibrx Biosciences files periodic reports with the U.S. Securities and Exchange Commission. All filings are available on the SEC's EDGAR system.
View on SEC EDGARInvestor Contact
Get in touch
For investor inquiries, please contact our investor relations team. We are committed to transparent and timely communication with our shareholders.
Forward-Looking Statements: This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Inhibrx Biosciences, Inc. undertakes no obligation to update any forward-looking statements.